Progression of JAK2- mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

Leuk Lymphoma. 2019 Dec;60(13):3296-3299. doi: 10.1080/10428194.2019.1633634. Epub 2019 Jul 1.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calreticulin / genetics*
  • DNA Mutational Analysis
  • Disease Progression
  • Erythropoietin / therapeutic use
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunologic Factors / therapeutic use
  • Janus Kinase 2 / genetics*
  • Male
  • Middle Aged
  • Mutation
  • Polycythemia Vera / blood
  • Polycythemia Vera / genetics*
  • Polycythemia Vera / pathology
  • Primary Myelofibrosis / blood
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / pathology
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • CALR protein, human
  • Calreticulin
  • Immunologic Factors
  • Erythropoietin
  • JAK2 protein, human
  • Janus Kinase 2